Leucemia Mielóide Crônica: história natural e classificação

Bortolheiro, Teresa Cristina; Chiattone, Carlos S.

doi:10.1590/s1516-84842008000700003

Cited by 23 publications

(24 citation statements)

References 13 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies in Brazil have shown the median age at diagnosis to be at least 10 years lower than that found in the international literature (20,21). Data from the present study corroborate a study by Bortolheiro and Chiattone (22), where patients with disease refractory to interferon-alpha had a median age at diagnosis of 40 years.…”

Section: Resultssupporting

confidence: 88%

Comparison of BCR–ABL Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines

Sales

Mesquita

Portilho

et al. 2019

In Vivo

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 88%

Comparison of BCR–ABL Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines

Sales

Mesquita

Portilho

et al. 2019

In Vivo

View full text Add to dashboard Cite

“…It affects all ages, but the incidence rises with age (21) . The average age at diagnosis is 55 to 60 years, with less than 10% of patients being younger than 20 years old (21,22) .…”

Section: Discussionmentioning

confidence: 99%

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Petrola¹,

Castro²,

Pitombeira³

et al. 2012

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

Background: Chronic myeloid leukemia is a neoplasm characterized by clonal expansion of hematopoietic progenitor cells resulting from the (9:22)(q34,11) translocation. The tyrosine kinase abl fusion protein,the initial leukemogenic event in chronic myeloid leukemia, is constitutively activated thus inducing the production of reactive oxygen species. Of particular relevance is the fact that an increase in reactive oxygen species can facilitate genomic instability and may contribute to disease progression. Objetive: To evaluate oxidative stress by determining the levels of malondialdehyde and nitrite in chronic myeloid leukemia patients under treatment with 1st and 2nd generation tyrosine kinase inhibitors monitored at a referral hospital in Fortaleza, Ceará. Methods: A cross-sectional study was performed of 64 male and female adults. Patients were stratified according to treatment. The levels of malondialdehyde and nitrite were determined by spectrophotometry. Statistical differences between groups were observed using the Student t-test and Fisher's exact test. The results are expressed as mean ± standard error of mean. The significance level was set for a p-value < 0.05 in all analyses. Results: The results show significantly higher mean concentrations of nitrite and malondialdehyde in chronic myeloid leukemia patients using second-generation tyrosine kinase inhibitors compared to patients on imatinib. Conclusion: It follows that chronic myeloid leukemia patients present higher oxidative activity and that the increases in oxidative damage markers can indicate resistance to 1st generation tyrosine kinase inhibitors.

show abstract

“…CML occurs in three phases (chronic, accelerated and blast crisis) and is usually diagnosed during chronic phase (Bortolheiro and Chiattone, 2008).…”

Section: Introductionmentioning

confidence: 99%

Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil

Silveira¹,

Daldegan²,

Ferrari³

2011

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We analyzed the results of treatment with imatinib mesylate in 70 patients with chronic-phase chronic myeloid leukemia who had previously been treated (with second-line or higher imatinib), many of them in a late chronic phase. The median followup period was 60.5 months (range 3-100 months). Our objective was to assess the efficacy and safety of treatment. The mean dose was 400 mg per day. The hematologic response rate was 92.1% at six months, while the cumulative rates of major and complete cytogenetic responses were 73.6 and 66.3%, respectively. Molecular response rate improved slowly and steadily over time, reaching 65.8% at 60 months, remaining stable for up to 96 months. The five-year progression-free survival and overall survival were 84 and 89%, respectively. Cytogenetic response by 12 months significantly correlated with overall survival (P = 0.0007) and progression-free survival (P = 0.0280). Sokal risk score did not differ significantly between subgroups. The medication was well tolerated, with only Imatinib mesylate in chronic myeloid leukemia 16% of patients showing hematologic toxicity grades 3 and 4. At the end of the assessment, 57% of the patients were still on imatinib mesylate; most of those who discontinued treatment (17/30) did so because of unsatisfactory response. Treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia induced durable responses in a high proportion of patients and was related to satisfactory long-term and event-free survival.

show abstract

Leucemia Mielóide Crônica: história natural e classificação

Cited by 23 publications

References 13 publications

Comparison of BCR–ABL Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines

Comparison of BCR–ABL Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil

Contact Info

Product

Resources

About